newsfilter
← Latest News
Business Wire·

BeOne Medicines Showcases Leadership in B-cell Malignancies at ASH 2025

BRUKINSA now demonstrates best-in-class sustained efficacy and long-term benefit with a favorable safety profile over more than six years of follow-up data in treatment-naïve and R/R CLL First results from Phase 1/2